Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 10/20 | 0.61 |
| ▸ | NMUR1 | Q9HB89 | 10/20 | 0.61 |
| ▸ | NPY4R | P50391 | 7/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.59 |
| ▸ | NPY1R | P25929 | 5/20 | 0.59 |
| ▸ | NPY2R | P49146 | 3/20 | 0.59 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402688 | 1.00 | NMUR2 (0.61) | NMUR2NMUR1NPY4RNPY5RNPY1R | |
| SCHEMBL13402656 | 0.91 | NMUR2 (0.59) | NMUR2NMUR1 | |
| SCHEMBL13402440 | 0.90 | OPRM1 (0.57) | NMUR2NMUR1NPY4RNPY5RNPY1R | |
| SCHEMBL13402505 | 0.88 | NMUR2 (0.59) | NMUR2NMUR1NPY4RNPY5RNPY1R | |
| SCHEMBL13402619 | 0.84 | OPRM1 (0.58) | NMUR2NMUR1NPY1RNTSR2NTSR1 | |
| SCHEMBL13402428 | 0.84 | OPRM1 (0.58) | NMUR2NMUR1NPY4RNPY5RNPY1R | |
| SCHEMBL13402652 | 0.84 | NMUR2 (0.59) | NMUR2NMUR1NPY4RNPY5RNPY1R | |
| SCHEMBL13402651 | 0.84 | NMUR2 (0.59) | NMUR2NMUR1NPY4RNPY5RNPY1R | |
| SCHEMBL13402670 | 0.84 | OPRM1 (0.62) | NMUR2NMUR1NPY4RNPY5RNPY1R | |
| SCHEMBL13402665 | 0.83 | NMUR2 (0.51) | NMUR2NMUR1NPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087466-A1 | NOVEL SMALL MOLECULE DNAK INHIBITORS | CHAPERONE TECHNOLOGIES, INC. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087466-A1 | NOVEL SMALL MOLECULE DNAK INHIBITORS | HSP90AB2P, HSPH1, HSP90AB1 | NMUR2 4123/4885NMUR1 3964/4885NPY4R 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.